Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Next Previous
Trial Profile

An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CheckMate057
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 06 Nov 2019 Results analysing the accuracy of different extrapolations performed at early data cuts in predicting realised long-term life years based on the CheckMate 057 study of nivolumab presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 10 Sep 2019 Results of Taylor-Expansion Adjustment for Survival Analyses in Immunotherapy Trials, presented at the 20th World Conference on Lung Cancer.
    • 10 Sep 2019 Five-Year outcomes from the randomized, phase 3 trials CheckMate 017/057; results presented at the 20th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top